Data asset leverage Target pharma and biotech firms seeking real‑world data assets to de-risk trials and accelerate product lifecycles; Prognos Health’s large de‑identified patient dataset and lab/claims integration can support market access, conducting post‑approval studies, and evidence generation for value dossiers.

Precision marketing edge Sell to life sciences brands and contract research organizations on Prognos’s lab data powered precision marketing offerings such as Pinpoint HCP and daily alerts; emphasize ability to improve HCP targeting, engagement effectiveness, and ROI for campaigns.

Collaborations & ecosystems Highlight partnership opportunities with CROs, diagnostic labs, and digital health platforms (e.g., Massive Bio collaboration) to expand data-driven services, co‑develop solutions, and access broader customer networks.

Global market signals Position Prognos as a scalable, cloud‑based RWD marketplace suitable for global trials; demonstrate flexibility across payer, provider, and researcher use cases to align with customers pursuing diverse geographies and regulatory environments.

Growth and credibility Leverage the company’s growth trajectory, recent product launches (Oncology, precision marketing suite, HCP alerts) and active funding to reassure potential buyers of ongoing innovation, support, and roadmap alignment with enterprise procurement cycles.